ROARABLE
Today ⌘ Pro Terminal Big Ideas 🎲 Predictions Screener 🦋 Butterfly 8 Analysts 🏛️ Policy 🎬 Video ★ Watchlist 🎲 Prediction Markets 📊 RQD Track Record 📅 Next Catalysts 🛡️ Overlap & Crash X-Ray 📰 Live Wire 🐋 13F Whales 🏛️ Congress & CEO Buys 🏆 $100K Arena ⌘ Pro Terminal 📐 Methodology & Corrections
Stock Ratings / Health Care / TNGX
IRON (54) XENE (37) OGN (70) AMLX (39) ⌘ Pro Terminal →

Tango Therapeutics Inc. (TNGX) — RQD Stock Rating Cockpit

$22.72 +0.84% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $22.71

Tango Therapeutics Inc. (TNGX) carries a Roarable Rating of D (Sell) with 44/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (44/100 · D) historically underperformed SPY in 71% of rolling 90-day windows →
ROARABLE D • SELL / AVOID Cap $3.80B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on TNGX Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is TNGX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-02, Tango Therapeutics Inc. (NASDAQ: TNGX) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 44/100 at a spot price of $22.72 (+0.84% 1D, market cap $3.80B). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, TNGX ranks #426 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does TNGX compare to IRON and XENE in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), TNGX carries a Roarable D (44/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -28.9%. By comparison, IRON (Disc Medicine Inc.) holds a D+ grade (54/100 RQD, P/E N/A, ROIC -27.5%, cap $3.68B) and XENE (Xenon Pharmaceuticals Inc.) posts a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $3.64B). Among the 5-stock peer group, OGN leads on earnings multiple (19.4x) while OGN leads on capital efficiency (24.9% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for TNGX?
▼

Per TNGX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001819133), Tango Therapeutics Inc. generated $62.4M in revenue (+48.3% YoY), -$101.6M in net income, and -$139.9M in free cash flow against $398.7M in total assets and $23.6M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $22.71 (-0.04%)🧬 Dilution Drag (+1.92% YoY Shares)⚙️ Cash Engine: 5/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (44/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-6.5% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D
025507510044
2-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk C
Cash (5)Whales (9)SEC (14)Macro (11)CEO (5)
Each axis scored 0–20
12M PRICE TARGET CONE-6.3% Base Target
$36 Bull$21 Base$17 Bear
📬 FREE TNGX RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for TNGX)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (44/100 Composite)
🔍 WHY TNGX SCORES 44/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+14/20 pts (32% of score)

Altman Z-Score 26.00 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 5/9

▲ #2 Bullish Driver: Macro Regime Fit+11/20 pts (25% of score)

FRED Regime × Technicals: 57% of 52W Range • RSI-14 at 46 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Dilution Drag (+1.92% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
36
Grade E$22.22+13.6% Next Q
Q2 (-2Q)
39
Grade E$25.25-9.3% Next Q
Q3 (-1Q)
41
Grade D$22.89-0.7% Next Q
Current
44
Grade D$22.72-6.5% Hist 90D α
Trajectory: E (36) → D (44)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a TNGX Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While TNGX currently carries a cautious 44/100 (D) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($23.54) and Max Pain ($23.86) forces dealer call-delta covering toward $36.11.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.92% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $TNGX• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “TNGX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 44%NO 56%Trade / Inspect Odds →
RSI-14 MOMENTUMNEUTRAL RANGE
4630 Oversold · 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
26.00>3.0 Fortress Safe
PIOTROSKI F-SCORESOLID CORE (5–6)
5 / 99-Pt Accounting
52-WEEK LASER RANGE57% OF RANGE
L: $7$22.72H: $34
1. Money & Cash Health● WEAK
Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: ERQD 5 / 20
2. Big Money & Insiders● TRIMMING
Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: D-RQD 14 / 40
3. Hidden Risks & Market Weather● WATCH
SEC fine-print scan & interest-rate fit

No major SEC filing blowups, though current interest rates and Fed liquidity call for normal position sizing.

Factor Grade: CRQD 25 / 40
MULTI-MODEL JEV QUANT JURY DELIBERATION

2-of-3 JEV AI Jury Bearish Warning on TNGX

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BEARISH (25)

-28.9% ROIC with 42.0% gross margin and -3.68% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
BULLISH (70)

Altman-Z 26.00 and Piotroski 5/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BEARISH (42)

14/40 institutional & smart-money positioning score with 11/20 macro alignment.

Bull Case: Why Buyers Like TNGX
  • ✓Established market leader in Health Care with deep daily trading liquidity.
Bear Case: What Could Go Wrong
  • !Company executives have done more routine share selling than personal cash buying lately.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring TNGX)

  • ✓Walkthrough of TNGX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
TNGX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +0.04%📐 HORIZONTAL RANGE
2026-11-02O $22.23H $22.72L $22.23C $22.72VOL 3.37M
RES: $28.18SUP: $20.50SMA50: $23.54SMA200: $22.43
$35.99$29.35$22.72$16.08$9.44RES $28.18SUP $20.50$22.722026-05-042026-06-172026-08-042026-09-182026-11-02
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

TNGX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 TNGX Butterfly Map → + Track TNGX →
Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
21.4%/yr Implied 5Y Growth

vs. +48.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on TNGX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for TNGX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for TNGX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (TNGX)

Health Care Rank #426 of 1016 ⚔️ IRON vs TNGX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (TNGX vs. IRON, XENE, OGN, AMLX)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Tango Therapeutics Inc. (TNGX) ranks #426 by composite RQD confidence (44/100, grade D) and #186 by equity capitalization ($3.80B). Within this direct 5-issuer industry benchmark cohort, OGN leads on earnings valuation at 19.4x trailing P/E, while OGN leads on capital efficiency and profitability with 24.9% ROIC and 53.3% gross margin. OGN currently holds the highest overall quantitative score in the immediate peer group at 70/100 (B-) compared with TNGX at 44/100 (D).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
TNGX ACTIVE
Tango Therapeutics Inc.
D 44/100 — — -28.9% +0.84% $3.80B Benchmark Subject
IRON
Disc Medicine Inc.
D+ 54/100 — — -27.5% -2.41% $3.68B /iron-vs-tngx →
XENE
Xenon Pharmaceuticals Inc.
D- 37/100 — — -35.0% -0.35% $3.64B /xene-vs-tngx →
OGN
Organon & Co.
B- 70/100 19.4x 53.3% 24.9% +0.22% $3.63B /ogn-vs-tngx →
AMLX
Amylyx Pharmaceuticals Inc.
D- 39/100 — — -35.0% +0.63% $3.60B /amlx-vs-tngx →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001819133

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Tango Therapeutics Inc. (TNGX) reported GAAP revenue of $62.4M (+48.3% vs. FY2024 revenue of $42.1M , and +70.8% cumulative change since FY2023) , GAAP net income of -$101.6M, operating cash flow of -$138.9M, and free cash flow of -$139.9M (-5.8% YoY). On the balance sheet, TNGX closed FY2025 with $398.7M in total assets against $23.6M in total debt (Altman Z-Score: 26.00, Piotroski F-Score: 5/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $62.4M -$101.6M -$138.9M -$139.9M $398.7M $23.6M
FY2024 (FY) 2024-12-31 $42.1M -$130.3M -$131.5M -$132.3M $316.5M $52.6M
FY2023 (FY) 2023-12-31 $36.5M -$101.7M -$118.0M -$119.6M $2.09B $488.9M

3. TNGX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is TNGX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-02, Tango Therapeutics Inc. (NASDAQ: TNGX) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 44/100 at a spot price of $22.72 (+0.84% 1D, market cap $3.80B). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, TNGX ranks #426 in composite RQD confidence.

How does TNGX compare to IRON and XENE in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), TNGX carries a Roarable D (44/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -28.9%. By comparison, IRON (Disc Medicine Inc.) holds a D+ grade (54/100 RQD, P/E N/A, ROIC -27.5%, cap $3.68B) and XENE (Xenon Pharmaceuticals Inc.) posts a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $3.64B). Among the 5-stock peer group, OGN leads on earnings multiple (19.4x) while OGN leads on capital efficiency (24.9% ROIC).

What are the biggest fundamental strengths and SEC risk factors for TNGX?

Per TNGX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001819133), Tango Therapeutics Inc. generated $62.4M in revenue (+48.3% YoY), -$101.6M in net income, and -$139.9M in free cash flow against $398.7M in total assets and $23.6M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is TNGX trading relative to its 50-day, 200-day, and 52-week technical levels?

TNGX last traded at $22.72 (+0.84% on volume of 5,279,477 shares), positioning the stock -3.48% below its 50-day simple moving average ($23.54) and +1.29% above its 200-day simple moving average ($22.43). Across its 52-week range of $7.37 to $34.39, TNGX sits at the 56.8% percentile with a 14-day RSI of 46.0 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($19.88 to $25.56).

TNGX Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell TNGX stock right now?

Tango Therapeutics Inc. (TNGX) currently earns a Roarable Rating of D (Sell — SELL) with 44/100 RQD Confidence. Stretched risk/reward at current multiples (-29% return on capital) under elevated 10-year interest-rate pressure.

What is TNGX's 12-month price target and RQD AI Jury consensus?

TNGX's 12-month base price target is $21.29 (range $16.61 to $36.11), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: TNGX RQD Cockpit TNGX 12M Forecast TNGX Earnings & Move TNGX Dividends & DRIP TNGX Insiders & 13F TNGX Whale Options TNGX Profit Sankey TNGX News & Why
ROARABLE RATING BRIEF • RQD 44/100 (D) ✓ STAGE-C NUMBER FIREWALL VERIFIED

TNGX — Tango Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:22:50Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, TNGX scores 44 out of 100, a letter grade of D, with the verdict "Roarable Sell — Underperform / Distribution Warning." The five pillars are:

  • Fundamental Cash Engine: 5 / 20. Per the RQD rating, this reflects ROIC of -28.9% and an FCF yield of -3.68%. The reported FY 2025 free cash flow of $-139.9M shows the business is consuming cash rather than generating it.
  • Whale 13F Flow: 9 / 20. Per the RQD rating, this reflects institutional accumulation and options positioning. The underlying holder detail is not provided in the holders section (see Analyst View).
  • Insider Conviction: 5 / 20. Per the RQD rating, this reflects SEC Form 4 and Congressional PTR cluster flow scored weakly.
  • Macro Regime Fit: 11 / 20. Per the RQD rating, this reflects a beta of 0.87 and sector sensitivity.
  • Forensic Balance Sheet: 14 / 20. Per the RQD rating, this reflects Altman Z 26, Piotroski F 5/9, and Debt/Equity 0.06. This is the strongest pillar, though it is still not a high score.

For a prospective investor evaluating the stock today, the rating points to a cash-burn profile. Operating margin is -60% and the company reports negative EPS (TTM) of -0.6. The balance-sheet pillar offers some comfort on solvency, but the cash-engine and insider-conviction pillars weigh the score down. The forward P/E of 28 is presented alongside negative trailing earnings, so the valuation depends on future earnings that the source data does not project. The rating is an analytical scoring output, not a recommendation.

Financial Trend

PeriodRevenueOperating IncomeNet IncomeEPSFCFCashDebt
FY 2025$62.4M$-111.3M$-101.6MN/A$-139.9M$112.3M$23.6M
FY 2024$42.1M$-145.6M$-130.3MN/A$-132.3M$69.5M$52.6M
FY 2023$36.5M$-114.2M$-101.7MN/A$-119.6MN/A$488.9M

Per the SEC financials, revenue grew from $36.5M (FY 2023) to $62.4M (FY 2025), while operating losses persisted in every period shown. Per the market data, gross margin is 0%, operating margin is -60%, and net margin is -60%, with ROIC at -28.9%. Per the RQD rating, the Altman Z-Score is 26 and the Piotroski F-Score is 5/9. Debt fell from $488.9M (FY 2023) to $23.6M (FY 2025), and reported cash was $112.3M at FY 2025, indicating a stronger balance sheet than the prior year despite ongoing cash burn.

Recent Catalysts & News Wire Analysis

Per the recent news section, headlines reference pancreatic cancer data, a JPMorgan rating reiteration ahead of ESMO data, comparisons to Revolution's results, updated vopimetostat combination data, a stock that has run 252%, and a report that the stock traded lower after cancer drug data. Each item is tagged YELLOW under the MARKET WIRE impact label. Per the Butterfly graph, there are no proprietary signals and no supply-chain links. Risk watch items include the trading-lower reaction to data and the valuation concern raised in the "fully valued" headline.

Open Questions

  • What specific products and clinical programs does Tango Therapeutics commercialize, and what generates its $62.4M of FY 2025 revenue?
  • What is the source of the reported 252% run and the 52-week range move from $7.37 to $34.39?
  • What is the cash runway given FY 2025 free cash flow of $-139.9M against reported cash of $112.3M?
  • What are the institutional and insider holdings behind the 9/20 whale-flow and 5/20 insider-conviction pillar scores?
  • What trailing P/E and EV/EBITDA apply, given both are absent from the source data?

TNGX Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Tango Therapeutics Inc. (TNGX) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to TNGX Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

TNGX Bull vs. Bear Conversation Board — What's Your Call at $22.72?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON TNGX 🐻 67% BEARISH CONVICTION
1. Pick Your Side on TNGX:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $19.83 (-12.0%)
📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is TNGX (D • RQD 44/100) a Buy at $22.53?

Welcome to the TNGX (Tango Therapeutics Inc.) Roar Pit. Current RQD Composite is 44/100 (Roarable Sell — Underperform / Distribution Warning) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

MU MultipleCompression Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $18.93 (-16.0%)
Spot @ $22.53

Pump the brakes on TNGX — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on TNGX, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Tango Therapeutics Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

TA TapeReader_Pro Verified K Arena Trader 🐂 BULLISH 🎯 Target: $27.94 (+24.0%)
Spot @ $22.53

TNGX cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on TNGX, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $22.53 (52-wk range $7.37 - $34.39), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $755.72 -0.38% QQQ $690.49 -1.44% DIA $517.13 -0.37% IWM $279.33 +0.96% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.36 -0.94% GLD $355.78 -1.34%